Tag: Health Care

Displaying 321 - 340 of 802 results.

I commend the House Energy and Commerce Committee for adopting the Protecting Consumer Access to Generic Drugs Act (H.R.1706) as an amendment to the omnibus health reform legislation. If enacted into law, this measure will put an end to the sweetheart deals between brand and generic pharmaceutical...
The Commission authorized a preliminary injunction to block Thoratec Corporation’s proposed $282 million acquisition of rival medical device maker HeartWare International, Inc., charging that the transaction would substantially reduce competition in the U.S. market for left...
The Federal Trade Commission has authorized a lawsuit to block Thoratec Corporation’s proposed $282 million acquisition of rival medical device maker HeartWare International, Inc., charging that the transaction would substantially reduce competition in the U.S. market for left ventricular devices...
The Commission issued an administrative complaint challenging Carilion Clinic’s 2008 acquisition of two competing outpatient clinics in the Roanoke, Virginia, area. The complaint alleges that Carilion’s acquisition of these outpatient centers eliminated competition for patients in...
The Federal Trade Commission has issued an administrative complaint challenging Carilion Clinic’s 2008 acquisition of two outpatient clinics in the Roanoke, Virginia, area. Prior to the acquisition, the Center for Advanced Imaging (CAI) and the Center for Surgical Excellence (CSE) had strong...
The Federal Trade Commission today told the Senate Subcommittee on Consumer Protection, Product Safety, and Insurance of the Committee on Commerce, Science & Transportation that competition and the agency’s antitrust enforcement improves health care in the United States in two ways – first, by...
The Federal Trade Commission today issued “Authorized Generics: An Interim Report,” which presents the first set of results from a study conducted to examine the short-term and long-term effects of “authorized generics” on competition in the prescription drug marketplace. An authorized generic...
In a speech today before the Center for American Progress in Washington, D.C., Federal Trade Commission Chairman Jon Leibowitz said that an internal FTC analysis projects that stopping collusive “pay-for-delay” settlements between brand and generic pharmaceutical firms would save consumers $3.5...
Testifying today on behalf of the Federal Trade Commission before the Subcommittee on Health of the U.S. House of Representatives Energy and Commerce Committee, Commissioner Pamela Jones Harbour presented the findings and recommendations of the FTC’s new Report, “Follow-on Biologic Drug...
The Federal Trade Commission today released a report entitled “Follow-on Biologic Drug Competition”which examines whether the price of biologic drugs – products manufactured using living tissues and microorganisms – could be reduced by competition from so-called “follow-on biologics” (FOBs). FOBs...
Following the Federal Trade Commission’s filing of a lawsuit to block the transaction, CSL Limited announced on June 8, 2009, that it will not proceed with its proposed $3.1 billion acquisition of Talecris Biotherapeutics. The FTC’s complaint charged that the deal would be illegal and would...
Federal Trade Commission Chairman Jon Leibowitz, Commissioner Pamela Jones Harbour, and Commissioner William E. Kovacic have issued a joint statement in response to the announcement by Endocare, Inc., that it has terminated its merger agreement with Galil Medical Ltd. during the agency’s ongoing...
Alta Bates Medical Group, Inc., a 600-physician independent practice association serving the Berkeley and Oakland, California, area, settleed Commission charges that it violated federal antitrust law by fixing prices charged to health care insurers. The consent order prohibits Alta...
Alta Bates Medical Group, Inc. (Alta Bates), a 600-physician independent practice association serving the Berkeley and Oakland, California, area, has agreed to settle Federal Trade Commission charges that it violated federal antitrust law by fixing prices charged to health care insurers. A...
Testifying today on behalf of the Federal Trade Commission before the U.S. House Judiciary Committee’s Subcommittee on Courts and Competition Policy, Bureau of Competition Director Richard A. Feinstein said that anticompetitive patent settlements in the U.S. pharmaceutical industry delay consumer...
On 2/2/2009, the Commission filed a complaint in federal district court challenging and agreement between Solvay Pharmaceuticals and two generic drug manufacturers in which Solvay paid for the delayed release of generic equivalents to its own testosterone-replacement drug, AndroGel,...
The FTC authorized a lawsuit to block CSL Limited’s proposed $3.1 billion acquisition of Talecris Biotherapeutics Holdings Corporation, charging that the deal would would substantially reduce competition in the U.S. markets for four plasma-derivative protein therapies – Immune...
The Federal Trade Commission has authorized a lawsuit to block CSL Limited’s proposed $3.1 billion acquisition of Talecris Biotherapeutics Holdings Corporation, charging that the deal would be illegal and would substantially reduce competition in the U.S. markets for four plasma-derivative protein...

Pages